Selvais P, Donckier J, Buysschaert M, Maiter D
Division of Endocrinology and Nutrition, University Hospital Saint Luc, Brussels, Belgium.
Eur J Endocrinol. 1998 Feb;138(2):153-9. doi: 10.1530/eje.0.1380153.
Cushing's disease appears as a functionally heterogeneous disease, but criteria that are able to distinguish between different clinical forms remain elusive. We compared two subgroups of patients with proven Cushing's disease according to the size of the pituitary adenoma, evaluated by computed tomography or magnetic resonance imaging. Our series comprised 11 patients with a microadenoma and 10 with a macroadenoma (median volumes (range): 173 (13-270) and 3022 (500-10312) mm3 respectively; P < 0.0001). The clinical presentation was similar in the two groups, but the time elapsed before diagnosis was longer, and visual impairment was less frequent in the patients with a microadenoma (1.5+/-0.8 years and 0%) than in those with a macroadenoma (0.7+/-0.6 years and 40%; P < 0.05). Morning and evening peripheral concentrations of ACTH were greater in patients with macroadenoma (134+/-78 and 130+/-7 ng/l respectively) than in those with microadenoma (52+/-28 and 56+/-19 ng/l, P < 0.05). Hypokalaemia and lymphopenia were also more pronounced in patients with macroadenoma (3.4+/-0.3 mmol/l and 1273+/-401 lymphocytes/mm3) than in those with microadenoma (3.8+/-0.3 mmol/l and 1852+/-668 lymphocytes/mm3 P < 0.05), although morning and evening plasma cortisol concentrations were similar in both groups. In patients with macroadenoma, there was less relative nycthemeral variation of ACTH concentrations (28+/-24%, compared with 62+/-39% in those with microadenoma; P < 0.05), less suppression of plasma cortisol by high doses of dexamethasone (-30+/-14%, compared with -61+/-25%; P < 0.05), and a reduced concentration ratio of mean basal cortisol to ACTH (7+/-3, compared with 12+/-5; P < 0.05). Plasma IGF-I concentration and the TSH peak response to TRH were significantly lower in patients with macroadenoma than in those with microadenoma (0.4+/-0.2 x 10(3) IU/I and 2.3+/-1.8 mIU/I, compared with 1.8+/-0.6 x 10(3) IU/I and 5.2+/-1.6 mUI/l; P < 0.05). Thus, in comparison with microadenomas, corticotroph macroadenomas are characterized by a greater and more autonomous ACTH secretion, inducing more pronounced biological signs of hypercorticism, and are more often accompanied by visual field defects and impairment of other pituitary hormonal secretions.
库欣病表现为一种功能异质性疾病,但能够区分不同临床类型的标准仍不明确。我们根据通过计算机断层扫描或磁共振成像评估的垂体腺瘤大小,比较了两组经证实患有库欣病的患者。我们的研究系列包括11例微腺瘤患者和10例大腺瘤患者(中位体积(范围):分别为173(13 - 270)和3022(500 - 10312)mm³;P < 0.0001)。两组的临床表现相似,但微腺瘤患者在诊断前经过的时间更长,且视力损害的发生率低于大腺瘤患者(分别为1.5±0.8年和0%,而大腺瘤患者为0.7±0.6年和40%;P < 0.05)。大腺瘤患者上午和晚上外周血促肾上腺皮质激素(ACTH)浓度高于微腺瘤患者(分别为134±78和130±7 ng/L),而微腺瘤患者为52±28和56±19 ng/L,P < 0.05)。低钾血症和淋巴细胞减少症在大腺瘤患者中也比微腺瘤患者更明显(分别为3.4±0.3 mmol/L和1273±401个淋巴细胞/mm³),而微腺瘤患者为3.8±0.3 mmol/L和1852±668个淋巴细胞/mm³,P < 0.05),尽管两组上午和晚上的血浆皮质醇浓度相似。在大腺瘤患者中,ACTH浓度的相对昼夜变化较小(28±24%,而微腺瘤患者为62±39%;P < 0.05),高剂量地塞米松对血浆皮质醇的抑制作用较小(-30±14%,而微腺瘤患者为-61±25%;P < 0.05),且平均基础皮质醇与ACTH的浓度比降低(7±3,而微腺瘤患者为12±5;P < 0.05)。大腺瘤患者的血浆胰岛素样生长因子-I(IGF-I)浓度和促甲状腺激素(TSH)对促甲状腺激素释放激素(TRH)的峰值反应显著低于微腺瘤患者(分别为0.4±0.2×10³ IU/L和2.3±1.8 mIU/L,而微腺瘤患者为1.8±0.6×10³ IU/L和5.2±1.6 mU/L;P < 0.05)。因此,与微腺瘤相比,促肾上腺皮质激素大腺瘤的特点是ACTH分泌更多且更自主,导致皮质醇增多症的生物学体征更明显,并且更常伴有视野缺损和其他垂体激素分泌受损。